Annexon, Inc. ANNX
We take great care to ensure that the data presented and summarized in this overview for Annexon, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANNX
View all-
Satter Management Co., L.P.7.41MShares$20.4 Million71.99% of portfolio
-
Bvf Inc San Francisco, CA7MShares$19.3 Million0.59% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$18.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.3MShares$17.3 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.38MShares$14.8 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA5.25MShares$14.4 Million3.4% of portfolio
-
Bellevue Group Ag Kuesnacht, V85.16MShares$14.2 Million0.23% of portfolio
-
Logos Global Management LP San Francisco, CA4MShares$11 Million1.5% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.99MShares$11 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY3.4MShares$9.34 Million2.47% of portfolio
Latest Institutional Activity in ANNX
Top Purchases
Top Sells
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Insider Transactions at ANNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 14
2025
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
853
-0.65%
|
$1,706
$2.61 P/Share
|
|
Jul 14
2025
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,117
-0.91%
|
$2,234
$2.58 P/Share
|
|
Jul 14
2025
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
1,116
-1.05%
|
$2,232
$2.58 P/Share
|
|
Jun 30
2025
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
4,115
+12.16%
|
$8,230
$2.46 P/Share
|
|
Feb 18
2025
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
6,618
-7.1%
|
$13,236
$2.95 P/Share
|
|
Feb 18
2025
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
8,345
-11.99%
|
$16,690
$2.91 P/Share
|
|
Feb 18
2025
|
Dean Richard Artis EVP & CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
5,515
-6.17%
|
$11,030
$2.97 P/Share
|
|
Feb 18
2025
|
Jamie Dananberg CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,521
-14.16%
|
$11,042
$2.96 P/Share
|
|
Feb 18
2025
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,912
-8.16%
|
$13,824
$2.92 P/Share
|
|
Feb 13
2025
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
1,783
-2.5%
|
$3,566
$2.99 P/Share
|
|
Feb 13
2025
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,786
-2.07%
|
$3,572
$2.98 P/Share
|
|
Feb 13
2025
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,425
-1.51%
|
$2,850
$2.99 P/Share
|
|
Feb 13
2025
|
Douglas Love PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
5,021
-1.41%
|
$10,042
$2.95 P/Share
|
|
Jan 06
2025
|
Douglas Love PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,994
+9.63%
|
$37,994
$1.41 P/Share
|
|
Dec 02
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+11.11%
|
$16,000
$5.33 P/Share
|
|
Oct 30
2024
|
Douglas Love PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
114,449
+16.31%
|
$114,449
$1.85 P/Share
|
|
Oct 15
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
5,408
-7.04%
|
$37,856
$7.41 P/Share
|
|
Oct 15
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,408
+6.58%
|
$5,408
$1.85 P/Share
|
|
Oct 01
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+12.5%
|
$16,000
$5.97 P/Share
|
|
Sep 19
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Indirect |
4,500
-100.0%
|
$31,500
$7.1 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 158K shares |
|---|---|
| Open market or private purchase | 16.9K shares |
| Open market or private sale | 72.4K shares |
|---|